Table 3.
Patient Demographic and Clinical Characteristics
| Overall (N = 230) | GL (n = 81) | PL (n = 149) | |
|---|---|---|---|
| Age at first symptoms in y, mean (SD) | 19.2 (16.5) | 9.2 (11.9) | 24.7 (16.1) |
| Age at initial diagnosis in y, mean (SD) | 26.2 (18.4) | 12.3 (13.7) | 33.7 (16.1) |
| Age at first visit to treatment center in y, mean (SD) | 28.7 (18.2) | 16.1 (13.9) | 35.6 (16.6) |
| Years from first symptoms to diagnosis, mean (SD) | 6.9 (10.8) | 3.1 (6.4) | 9.0 (12.0) |
| Duration of follow-up period in y, mean (SD) | 7.6 (7.9) | 9.5 (8.1) | 6.5 (7.6) |
| Males, n (%) | 70 (30.4) | 33 (40.7) | 37 (24.8) |
| Race/ethnicity,a n (%) | |||
| Caucasian/white | 166 (72.2) | 46 (56.8) | 120 (80.5) |
| African descent/black | 17 (7.4) | 14 (17.3) | 3 (2.0) |
| Hispanic/Latino | 11 (4.8) | 2 (2.5) | 9 (6.0) |
| Other | 21 (9.1) | 16 (19.7) | 5 (3.4) |
| Unknown | 16 (7.0) | 3 (3.7) | 13 (8.7) |
| Country of residence, n (%) | |||
| Brazil | 52 (22.6) | 25 (30.9) | 27 (18.1) |
| Turkey | 80 (34.8) | 32 (39.5) | 48 (32.2) |
| United States | 93 (40.4) | 22 (27.2) | 71 (47.7) |
| Otherb | 5 (2.2) | 2 (2.5) | 3 (2.0) |
| Treatment center, n (%) | |||
| National Institutes of Health (United States) | 66 (28.7) | 23 (28.4) | 43 (28.9) |
| University of Michigan (United States) | 32 (13.9) | 1 (1.2) | 31 (20.8) |
| Dokuz Eylül University (Turkey) | 80 (34.8) | 32 (39.5) | 48 (32.2) |
| Federal University of Ceará (Brazil) | 23 (10.0) | 19 (23.5) | 4 (2.7) |
| Universidade de São Paulo (Brazil) | 29 (12.6) | 6 (7.4) | 23 (15.4) |
| Type of lipodystrophy, n (%) | |||
| AGL | 7 (3.0) | 7 (8.6) | — |
| APL | 28 (12.2) | — | 28 (18.8) |
| CGL | 72 (31.3) | 72 (88.9) | — |
| FPLD | 121 (52.6) | — | 121 (81.2) |
| Generalized progeroid lipodystrophy | 2 (0.9) | 2 (2.5) | — |
a
One patient in the United States was marked as “Caucasian” and “Other.” Because of this, the sum of patient counts for the race/ethnicity categories may exceed the total number of patients.
b
Other countries included Argentina, Bahamas, Greece, Israel, and the United Kingdom.